Outsourcing has been labelled as one of this century’s “greatest
organizational and industry structure shifts”.
Pharma’s crutch
The general
model in the pharmaceutical and biotechnology industries sees market
authorization holders (MAH) rely on external partners to execute a
range of activities including the likes of research, development and
manufacturing.
Rising
pressure from the public regarding medicine price points compounds the appeal
of outsourcing as a route to cool costs and free up internal resource burdens.
But, as pharma continues to wrestle with stagnant innovation levels and high failure rates, despite the boost in funds poured into R&D pipelines, cheaper running costs are no longer the primary goal.
Download this eBook to discover the key outsourcing trends impacting today's pharma and biotech industries.